



Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia

Mark Bounthavong¹ · Javed Butler² · Chantal M. Dolan³ · Jeffrey D. Dunn⁴ · Kathryn A. Fisher³ · Nina Oestreicher^{5,6} · Bertram Pitt⁷ · Paul J. Hauptman⁸ · David L. Veenstra¹

Published online: 14 May 2019
© Springer Nature Switzerland AG 2019

Correction to: PharmacoEconomics (2018) 36(12):1463–1473
<https://doi.org/10.1007/s40273-018-0709-3>

Page 1467, Section 3 (Results), 1st paragraph, final sentence:

The sentence should read, “In addition, the patiromer-spiro­nolactone-ACEI arm was associated with 0.19 greater total expected QALYs gained than the ACEI-only arm (2.79 versus 2.60 QALYs, respectively).”

The original article can be found online at <https://doi.org/10.1007/s40273-018-0709-3>.

✉ David L. Veenstra
veenstra@uw.edu

- ¹ Department of Pharmacy, University of Washington, 1959 NE Pacific St, HSB H375-P, Box 357630, Seattle, WA 98195-7630, USA
- ² Division of Cardiology, Stony Brook University, Stony Brook, NY, USA
- ³ CMD Consulting, Sandy, UT, USA
- ⁴ Magellan Rx, Salt Lake City, UT, USA
- ⁵ Epidemiology, HEOR and Observational Research, Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, CA, USA
- ⁶ Department of Clinical Pharmacy, University of California, San Francisco, CA, USA
- ⁷ University of Michigan School of Medicine, Ann Arbor, MI, USA
- ⁸ Division of Cardiology, Department of Medicine, Saint Louis University School of Medicine, Saint Louis, MI, USA